A phase I/II randomized, assessor-blind, vehicle-controlled study to assess the safety, tolerability, and pharmacodynamics of DLQ03 in a wound healing model in patients with mild to moderate atopic dermatitis that are colonized with S. Aureus

Treatment-emergent (serious) adverse events ((S)AEs) throughout the study at every study visit, Concomitant medication throughout the study at every study visit, Vital signs (Pulse Rate (bpm), Systolic blood pressure (mmHg), Diastolic blood pressure (mmHg)) as per assessment schedule, Clinical laboratory tests (Hematology, blood chemistry and urinalysis) as per assessment schedule, ECG parameters (Heart Rate (HR) (bpm), PR, QRS, QT, QTcB, QTcF) as per assessment schedule, Local irritation grading scale